DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,850.00
+5.00 (0.13%)
At close: Aug 3, 2026

DongKoo Bio & Pharma Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
242,076242,688249,275215,686194,988155,149
Revenue Growth
-0.68%-2.64%15.57%10.62%25.68%11.45%
Gross Profit
142,951144,342151,887132,076117,86092,337
Operating Income
8,7229,24812,69114,61616,8368,139
Net Income
50,37650,2722,03611,8126,6149,327
Earnings Per Share
1769.061791.0075.00427.63238.29330.05
EPS Growth
-2288.00%-82.46%79.46%-27.80%2.16%

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
41,28735,16536,25022,89835,13632,100
Total Debt
128,107128,78286,64143,80434,32224,294
Net Cash (Debt)
-86,820-93,617-50,391-20,906813.887,806
Net Cash Growth
-----89.57%33.61%
Net Cash Per Share
-3044.02-3329.90-1856.67-756.8929.32276.23

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
5,915-4,28717,3443,58516,81917,903
Capital Expenditures
-15,684-17,656-21,866-13,845-4,978-4,266
Free Cash Flow
-9,769-21,944-4,522-10,26011,84113,637
Free Cash Flow Growth
-----13.16%514.06%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
59.05%59.48%60.93%61.23%60.45%59.51%
Operating Margin
3.60%3.81%5.09%6.78%8.63%5.25%
Pretax Margin
25.51%25.31%1.53%6.83%4.06%7.30%
Profit Margin
20.81%20.71%0.82%5.48%3.39%6.01%
FCF Margin
-4.04%-9.04%-1.81%-4.76%6.07%8.79%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
2.182.9464.3813.2425.6424.94
P/FCF Ratio
----14.3217.05
PS Ratio
0.430.610.530.730.871.50